A comparison of p-tau assays for the specificity to detect tau changes in Alzheimer's diseaseClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
Umeå University, Faculty of Medicine, Department of Clinical Sciences, Neurosciences.
Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Università di Bologna, Bologna, Italy; IRCC Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Università di Bologna, Bologna, Italy; IRCC Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France; Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Anhui, Hefei, China.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom; UK Dementia Research Institute at UCL, Cruciform Building, London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong; Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, WI, Madison, United States.
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden; Memory Clinic the Skåne University Hospital, Malmö, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Dipartimento di Scienze Biomediche e Neuromotorie, Alma Mater Studiorum Università di Bologna, Bologna, Italy; IRCC Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
Show others and affiliations
2025 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 21, no 4, article id e70208Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: We evaluated differences in p-tau levels between Alzheimer's disease (AD), a condition with brain-specific changes in p-tau, and amyotrophic lateral sclerosis (ALS), a condition associated with increases in peripheral p-tau levels.
METHODS: Cerebrospinal fluid and plasma from 668 participants were analyzed using immunoassays specific for the low-molecular-weight (LMW) tau isoforms present in the brain (i.e., p-tau217Lilly, p-tau181Lilly) and those that detect both LMW- and high-molecular-weight (HMW) tau expressed in the peripheral nervous system (i.e., p-tau217AlzPath, p-tau181UGOT).
RESULTS: Increases in plasma p-tau in ALS versus controls were significantly smaller for the LMW-specific p-tau assays (15.9%–20.5%) compared with non-specific assays (92.0%–121.3%). The LMW-specific p-tau assays showed significantly larger plasma p-tau increases in AD versus ALS, discriminating AD from ALS with areas under the curve (AUCs; 0.890.93) higher than the AUCs of the non-specific assays (0.54–0.74).
DISCUSSION: LMW-specific p-tau assays could be more useful in the diagnostic workup of AD, especially in population-based communities where conditions causing peripheral neuropathy are frequent.
Place, publisher, year, edition, pages
John Wiley & Sons, 2025. Vol. 21, no 4, article id e70208
Keywords [en]
Alzheimer's disease, amyotrophic lateral sclerosis, biomarker, blood, low-molecular-weight tau, p-tau
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:umu:diva-238718DOI: 10.1002/alz.70208PubMedID: 40289884Scopus ID: 2-s2.0-105004248623OAI: oai:DiVA.org:umu-238718DiVA, id: diva2:1958576
Funder
Familjen Erling-Perssons StiftelseEU, Horizon 2020, 860197EU, Horizon Europe, 101053962The Swedish Brain Foundation, ALZ2022-0006; FO2024-0048-TK-130; FO2022-0270The Kempe FoundationsKonung Gustaf V:s och Drottning Victorias FrimurarestiftelseKnut and Alice Wallenberg Foundation, 2022-0231; 2012.0091; 2014.0305; 2020.0232; 2023.0460Parkinsonfonden, 1412/22Stiftelsen Gamla TjänarinnorAlzheimerfonden, AF-980907; AF-994229; AF-930351; AF-939721; AF-968270; AF-994551The Swedish Brain Foundation, FO2021-0293; FO2023-0163; 2012-0262; 2012-0305; 2013-0279; 2016-0303; 2018-0310; 2020-0353; 2022-0309Swedish Research Council, 2022-00775; 2021-02219; 2017-00915; 2022-00732; 2023-00356; 2022-01018; 2019-02397; 2012-3167; 2017-03100Ulla-Carin Lindquist Foundation for ALS-ResearchWallenberg AI, Autonomous Systems and Software Program (WASP), 201809-2016862Region Västerbotten, 56103-70028292025-05-152025-05-152025-05-15Bibliographically approved